Key Developments: Cipla Ltd (CIPL.BO)

CIPL.BO on Bombay Stock Exchange

628.45INR
23 Oct 2014
Price Change (% chg)

Rs1.55 (+0.25%)
Prev Close
Rs626.90
Open
Rs630.60
Day's High
Rs634.00
Day's Low
Rs625.00
Volume
40,467
Avg. Vol
219,918
52-wk High
Rs639.05
52-wk Low
Rs366.70

Search Stocks

Latest Key Developments (Source: Significant Developments)

Cipla Medpro announces collaboration with generic pharmaceutical company
Thursday, 9 Oct 2014 12:02am EDT 

Cipla Ltd:Says Medpro Pharmaceutical (Pty) Ltd- a subsidiary company of Cipla Medpro has entered into a collaboration with TevaPharmaceutical(Pty) Ltd, an affiliate of Teva Pharmaceutical Industries Ltd (Teve).Says the collaboration is restricted to the territory of South Africa.Says the collaboration is a sales and distribution whereby Cipla Medpro will exclusively market Teva's broad pharamaceutical product portfolio in South Africa.  Full Article

Cipla Ltd signs definitive agreement
Saturday, 4 Oct 2014 05:25am EDT 

Cipla Ltd:Signs a definitive agreement with its existing Iranian distributor for setting up a manufacturing facility in Iran.Says the total contribution from the company over the next 3 years will include machinery, equipment, technical know-how and is expected to be about 2.25 billion Indian rupees for a 75 pct stake.Says the proposed investment is subject to completion of certain conditions precedent and applicable regulatory approvals.  Full Article

Gilead Sciences Inc announces generic licensing agreements with Cipla Ltd and others
Monday, 15 Sep 2014 06:30am EDT 

Gilead Sciences Inc:Says it has signed non-exclusive licensing agreements with seven India-based generic pharmaceutical manufacturers to expand access to its chronic hepatitis C medicines in developing countries.Agreements allow the companies - Cadila Healthcare, Cipla , Hetero Labs ,Mylan Laboratories, Ranbaxy Laboratories, Sequent Scientific and Strides Arcolab - to manufacture sofosbuvir and the investigational single tablet regimen of ledipasvir/sofosbuvir for distribution in 91 developing countries.Under the licensing agreements, the Indian companies receive a complete technology transfer of the Gilead manufacturing process to enable them to scale up production as quickly as possible.The licensees also set their own prices for the generic product they produce, paying a royalty on sales to Gilead to support product registrations, medical education and training, safety monitoring and other essential business activities.The licenses also permit the manufacture of sofosbuvir or ledipasvir in combination with other chronic hepatitis C medicines.  Full Article

Cipla Ltd announces commercial collaboration with S&D Pharma
Monday, 8 Sep 2014 06:02am EDT 

Cipla Ltd:Says a commercial collaboration with S&D Pharma in the Czech Republic and Slovakia.This collaboration will enable Cipla to focus on its core therapy areas, while S&D Pharma will be the key partner for generics.Cipla will be driving its respiratory product portfolio in both Czech Republic and Slovakia through a Cipla owned sales force team, managed by Cipla commercial head.S&D Pharma will physically distribute all products, including respiratory products, and this portfolio will increase over the next few years.  Full Article

Cipla Ltd's Medispray Laboratories approved acquisition of two manufacturing undertakings
Friday, 5 Sep 2014 08:01am EDT 

Cipla Ltd:Says a subsidiary - Medispray Laboratories Pvt Ltd approved the acquisition of two manufacturing undertakings.The consideration for the above two transactions are 290 mln Indian Rupees and 719.3 mln Indian Rupees respectively.  Full Article

Cipla Ltd and BioQuiddity Announce EU Commercial Partnership for OneDose-ReadyfusOR for Post-Surgical Pain Management
Thursday, 31 Jul 2014 07:30am EDT 

Cipla Ltd:Says Cipla Europe NV and BioQuiddity Inc enters into a commercial collaboration, covering the territory of the European Union and certain other European countries, for BioQuiddity's OneDose ReadyfusOR in regional anesthetic applications for post-surgical pain management.Intends to launch the CE Marked OneDose ReadyfusOR pre-filled with Ropivacaine under its own label into the German market late this year.  Full Article

Cipla Ltd's MSPL acquires Mabpharm
Thursday, 17 Jul 2014 06:57am EDT 

Cipla Ltd:Says a subsidiary Meditab Specialities Pvt Ltd (MSPL), has acquired 75 pct stake in Mabpharm Pvt Ltd(Mabpharm).The company was earlier holding 25 pct stake in Mabpharm.Consequent to the acquisition of the aforesaid stake, Mabpharm has now become 100 pct subsidiary of the company.Mabpharm is inter alia engaged in development of monoclonal anitbodies for treatment of cancer and auto-immune diseases.Financial terms of the acquisition were not disclosed.  Full Article

Cipla Ltd signs definitive agreement to acquire 51 pct. stake in pharmaceuticals manufacturing and distribution business in Yemen
Sunday, 29 Jun 2014 11:35pm EDT 

Cipla Ltd:Signs definitive agreement to acquire 51 pct. stake in a pharmaceuticals manufacturing and distribution business in Yemen (in turn owned by a UAE based parent company).Says it will pay $21 mln for this transaction, with additional considerations to be paid over next three years on achievement of agreed milestones.Closing of transaction is subject to completion of certain conditions precedent.  Full Article

Cipla Ltd updates on subsidiary company
Tuesday, 17 Jun 2014 04:28am EDT 

Cipla Ltd:Cipla (mauritius) Limited, wholly owned subsidiary of the company has signed definitive agreement with the company’s existing Sri Lankan distributor for acquisition of 60 pct stake in new company which will market the Company’s products in Sri Lanka.Consideration payable for the transaction is $14 mln.  Full Article

Cipla Ltd recommends payment of dividend
Thursday, 29 May 2014 08:50am EDT 

Cipla Ltd:Recommends payment of dividend of 2 Indian rupees per equity share (face value 2 rupees per equity share) for the year 2013-2014 amounting to 1.6058 bln rupees.Dividend, subject to the approval of shareholders, will be dispatched / credited on or after Aug. 27, 2014.  Full Article

Indian drugmaker Cipla to set up manufacturing plant in Iran

MUMBAI, Oct 7 - Indian generic drugmaker Cipla Ltd has agreed to set up a manufacturing plant in Iran, as part of its strategy to boost its presence in the country's $4 billion pharmaceuticals market that is growing at about 13 percent annually.

Search Stocks